Legal Opinion
Glaxo, Inc. v. Novopharm Ltd.
District Court, E.D. North Carolina
Decided September 17, 1993No. 91-759-CIV-5-BOPublishedCited by 7 opinions
1Opinion of the Court
ORDER
TERRENCE WILLIAM BOYLE, District Judge.
Plaintiff Glaxo Group Ltd. is the owner of United States Patent No. 4,521,431 covering a particular crystalline form of a chemical compound called ranitidine hydrochloride. 1 The ’431 patent expires in 2002. Plaintiff Glaxo Inc. is the United States subsidiary of Glaxo Group Ltd. and is the exclusive U.S. licensee of the ’431 patent. Defendant Novopharm infringed this patent on August 9, 1991, by filing an Abbreviated New Drug Application (ANDA) with the Pood and Drug Administration in which it sought to market ranitidine hydrochloride beginning in…
2Cases cited9 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- Ethicon, Inc. v. Donald J. Quigg, Commissioner of Patents & Trademarks and the United States Patent & Trademark OfficeCourt of Appeals for the Federal Circuit · 1988
- Amgen, Inc., Plaintiff/cross-Appellant v. Chugai Pharmaceutical Co., Ltd., and Genetics Institute, Inc.Court of Appeals for the Federal Circuit · 1991
- Paragon Podiatry Laboratory, Inc. v. Klm Laboratories, Inc.Court of Appeals for the Federal Circuit · 1993
- Rohm and Haas Company v. Crystal Chemical Company and Joe C. EllerCourt of Appeals for the Federal Circuit · 1983
4 more not listed; retrieve them via the Exa API.
3Cited by7 opinions
- Glaxo, Inc., and Glaxo Group Limited v. Novopharm, Ltd.Court of Appeals for the Federal Circuit · 1997
- Glaxo Inc. And Glaxo Group Limited v. Novopharm Ltd.Court of Appeals for the Federal Circuit · 1995
- SmithKline Beecham Corp. v. Apotex Corp.District Court, N.D. Illinois · 2003
- Glaxo Inc. v. Novopharm Ltd.District Court, E.D. North Carolina · 1996
- Elan Pharmaceuticals, Inc. v. Mayo Foundation for Medical Education & ResearchDistrict Court, N.D. California · 2000
2 more not listed; retrieve them via the Exa API.